A Novel Therapeutic Management for Diabetes Patients with Chronic Limb-Threatening Ischemia: Comparison of Autologous Bone Marrow Mononuclear Cells Versus Allogenic Wharton Jelly-Derived Mesenchymal Stem Cells

Scientists compared the safety and beneficial therapeutic effect of autologous bone marrow mononuclear cell versus allogeneic Wharton jelly-derived mesenchymal stem cells in diabetic patients with chronic limb-threatening ischemia.